Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 1,514

The DOI matches its Crossref record; 160 of the 160 references it cites were found in a registry or an index.

Targeting the dynamic HSP90 complex in cancer

Open access
Trepel, Jane, Mollapour, Mehdi, Giaccone, Giuseppe, Neckers, Len · 2010 · Nature Reviews Cancer

Abstract

The molecular chaperone heat shock protein 90 (HSP90) has been used by cancer cells to facilitate the function of numerous oncoproteins, and it can be argued that cancer cells are 'addicted' to HSP90. However, although recent reports of the early clinical efficacy of HSP90 inhibitors are encouraging, the optimal use of HSP90-targeted therapeutics will depend on understanding the complexity of HSP90 regulation and the degree to which HSP90 participates in both neoplastic and normal cellular physiology.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nrc2887

Cites

160 of 160 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 15

  1. Chiosis, G. & Tao, H. Purine-scaffold Hsp90 inhibitors. IDrugs 9, 778–782 (2006).
  2. Au, Q., Zhang, Y., Barber, J. R., Ng, S. C. & Zhang, B. Identification of inhibitors of HSF1 functional activity by high-content target-based screening. J. Biomol. Screen. 14, 1165–1175 (2009). · doi:10.1177/1087057109347472
  3. Modi, S. et al. Phase II trial of the Hsp90 inhibitor tanespimycin (Tan) + trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC). J. Clin. Oncol. Abstr. 26, 1027 (2008). · doi:10.1200/jco.2008.26.15_suppl.1027
  4. Hwang, M., Moretti, L. & Lu, B. HSP90 inhibitors: multi-targeted antitumor effects and novel combinatorial therapeutic approaches in cancer therapy. Curr. Med. Chem. 16, 3081–3092 (2009). · doi:10.2174/092986709788802999
  5. Reikvam, H., Ersvaer, E. & Bruserud, O. Heat shock protein 90 - a potential target in the treatment of human acute myelogenous leukemia. Curr. Cancer Drug Targets 9, 761–776 (2009). · doi:10.2174/156800909789271486
  6. Elfiky, A. et al. BIIB021, an oral, synthetic non-ansamycin Hsp90 inhibitor: phase I experience. J. Clin. Oncol. Abstr. 26, 2503 (2008). · doi:10.1200/jco.2008.26.15_suppl.2503
  7. Sequist, L. V. et al. A phase II trial of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor, in patients with relapsed and/or refractory stage IIIb or stage IV non-small cell lung cancer (NSCLC) stratified by EGFR mutation status. J. Clin. Oncol. Abstr. 27, 8073 (2009). · doi:10.1200/jco.2009.27.15_suppl.8073
  8. Dakappagari, N. et al. An investigation into the potential use of serum Hsp70 as a novel tumour biomarker for Hsp90 inhibitors. Biomarkers 15, 31–38 (2009). · doi:10.3109/13547500903261347
  9. Demetri, G. D. et al. Inhibition of the heat shock protein 90 (Hsp90) chaperone with the novel agent IPI-504 to overcome resistance to tyrosine kinase inhibitors (TKIs) in metastatic GIST: updated results of a phase I trial. J. Clin. Oncol. Abstr. 25, 10024 (2007). · doi:10.1200/jco.2007.25.18_suppl.10024
  10. Oude Munnink, T. H. et al. 89Zr-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft. Eur. J. Cancer 46, 678–684 (2009). · doi:10.1016/j.ejca.2009.12.009
  11. Le, H. C. et al. Proton MRS detects metabolic changes in hormone sensitive and resistant human prostate cancer models CWR22 and CWR22r. Magn. Reson. Med. 62, 1112–1119 (2009). · doi:10.1002/mrm.22137
  12. Chung, Y. L. et al. Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino, 17-demethoxygeldanamycin (17AAG) in human colon cancer models. J. Natl Cancer Inst. 95, 1624–1633 (2003). · doi:10.1093/jnci/djg084
  13. Liu, D. et al. Use of radiolabelled choline as a pharmacodynamic marker for the signal transduction inhibitor geldanamycin. Br. J. Cancer 87, 783–789 (2002). · doi:10.1038/sj.bjc.6600558
  14. Hadchity, E. et al. Heat shock protein 27 as a new therapeutic target for radiation sensitization of head and neck squamous cell carcinoma. Mol. Ther. 17, 1387–1394 (2009). · doi:10.1038/mt.2009.90
  15. Stuehler, C. et al. Selective depletion of alloreactive T cells by targeted therapy of heat shock protein 90: a novel strategy for control of graft-versus-host disease. Blood 114, 2829–2836 (2009). · doi:10.1182/blood-2009-06-224600

Cited by

See all 1,514

Metadata

Authors
Trepel, J., Mollapour, M., Giaccone, G., & Neckers, L.
Venue
Nature Reviews Cancer
Published
2010-08
Volume
10
Issue
8
Pages
537-549
ISSN
  • 1474-175X (ISSN-L)
  • 1474-1768
OpenAlex
W2060902443
Cited by
1,514
References
160
FWCI
6.60
Type
journal article
Language
en
Open access
bronze
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.